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G
aucher disease is the most 
common lysosomal storage 
disorder (Box 1). A deﬁ  ciency 
of the enzyme glucocerebrosidase 
(Figure 1) causes accumulation of 
the glycolipid glucocerebroside in 
macrophages throughout the body. 
In the viscera, glucocerebroside arises 
mainly from the biodegradation 
of red and white blood cells. In 
the brain, glucocerebroside arises 
from the turnover of complex lipids 
during brain development and the 
formation of the myelin sheath of 
nerves. The disease may be discovered 
as an incidental ﬁ  nding in the elderly 
because of mild thrombocytopenia 
or splenomegaly, or it may present 
early in life with hepatosplenomegaly, 
thrombocytopenia, anemia, and bone 
lesions.
Until 1990, treatment consisted 
only of palliative measures such as 
splenectomy and hip replacement. The 
development of enzyme replacement 
therapy for Gaucher disease, that 
is, exogenous administration of 
the missing enzyme, is a triumph 
of translational medicine. At the 
same time, powerful commercial 
interests may have been inﬂ  uential in 
physicians adopting a high-dose rather 
than a low-dose treatment schedule. 
Moreover, the high cost of enzyme 
replacement therapy forces us to 
consider what society can afford in the 
way of palliative treatments for very rare 
diseases.
The History of Enzyme 
Replacement Therapy
The possibility that the therapeutic 
replacement of enzymes missing 
from lysosomes could be achieved 
was ﬁ  rst raised by de Duve forty years 
ago when he wrote: “Any substance 
that is taken up intracellularly by an 
endocytic process is likely to end up 
within lysosomes. This obviously opens 
up many possibilities for interaction, 
including replacement therapy” [1].
Type 1 Gaucher disease, the most 
common type, seems a particularly 
suitable target for enzyme replacement 
therapy because of the lack of central 
nervous system involvement (visceral 
damage in Gaucher disease is reversible 
whereas the brain damage usually is 
not). By the 1970s, the underlying 
enzyme deﬁ  ciency had been identiﬁ  ed, 
and methods had been developed 
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Figure 1. Glucocerebrosidase Cleaves a 
Linkage within Glucosylceramide, a Normal 
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to purify the enzyme from human 
placenta in a high state of purity. Three 
groups of investigators then attempted 
to treat the disease by infusing 
exogenous enzyme. 
In the United States, at the National 
Institutes of Health in Bethesda, 
Maryland, the unaltered enzyme 
was infused directly into the venous 
circulation [2]; at City of Hope in 
Duarte, California, it was entrapped 
in red cell membranes coated with 
antibody in an effort to direct it to 
macrophages [3]. In Harrow, United 
Kingdom, the enzyme was delivered 
entrapped in liposomes [4]. Although 
some mildly encouraging results were 
achieved, it was clear that none of these 
approaches was likely to be translated 
into a useful treatment. 
The needed conceptual 
breakthrough was provided by 
the identiﬁ  cation of a mannose 
receptor on macrophages and the 
suggestion that this might prove 
useful in replacement therapy for 
Gaucher disease [5]. This led to the 
development of a modiﬁ  ed enzyme, 
processed to expose mannose, and 
to its production on an industrial 
scale from placentas. After the gene 
encoding the enzyme was cloned [6], a 
recombinant product became available.
The Pivotal Study
The ﬁ  rst study of commercially 
produced mannose-enriched 
glucocerebrosidase was carried out 
in Bethesda, Maryland, on only 12 
patients, presumably because of a 
limited supply of the enzyme [7]. 
Given this small cohort of patients, 
only a single dose (60 units/kg) was 
administered. This dose was given 
every two weeks to ten of the patients, 
while two patients received it weekly. 
This is manifestly an unusual dose 
schedule for a preparation with a 
circulating half-life of only about 
12 min that is being targeted to a 
relatively small number of receptors. 
Many of the patients studied did not 
live near Bethesda, and it is likely that 
the dose schedule that was chosen 
was based on convenience rather 
than on sound pharmacokinetic 
principles. Since it was unlikely that 
a second study would be launched 
if the ﬁ  rst failed, the investigators 
wisely used a very generous dose of 
enzyme to maximize the probability 
that the trial would be successful. 
Intravenous administration of the 
enzyme produced objective clinical 
improvement (such as reduced 
liver and spleen size and increased 
hemoglobin levels and platelet 
counts).
The enzyme was promptly approved 
and marketed. Since only a single dose 
had been tested, this was the dose 
that most physicians administered in 
clinical practice. But the preparation 
was extremely costly—about US$4.00 
per unit. At the dose used in the pivotal 
trial, a 70-kg patient would receive 
enzyme costing US$16,800 every two 
weeks.
Dosage Considerations
Visceral organ responses. But was 
the large dose given actually the dose 
required? There were no data, and 
many physicians were unwilling to give 
less than the dose that had been used 
in the pivotal trial. Moreover, since 
most physicians took care of only one 
or at most two patients with the disease, 
they were not in a position to perform 
a dose-ranging study. And industry 
had no interest in supporting studies 
to show that a lower dose yielded 
equivalent results.
But clinical trials carried out in 
our National Institutes of Health–
sponsored General Clinical Research 
Center quickly established that a 
quarter of the dose given at more 
frequent intervals was fully effective 
[8]. By 2000, a considerable body 
of data had accumulated, making it 
possible to perform meta-analyses of 
the relationship between the total 
monthly dose, the interval at which the 
dose is administered, and the decrease 
in the size of the liver. The results were 
clear (Figure 2) [9]. Even a dose of 
only 15 units/kg/mo, one-ninth of the 
dose given in the pivotal trial, resulted 
in an excellent clinical response. Most 
patients were receiving a substantial 
overdose of an extremely costly 
preparation. The data indicate that 
when very large doses are administered, 
the two-week time interval is adequate 
to give an optimal response, but when 
more modest doses are administered, 
more frequent infusions greatly 
improve the response [9]. 
Recent “consensus 
recommendations,” which were 
supported in part by the Genzyme 
Corporation, the manufacturers 
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Box 1. What Is Gaucher Disease?
Gaucher disease is an inherited 
metabolic disorder in which harmful 
quantities of a fatty substance called 
glucocerebroside accumulate in the 
spleen, liver, lungs, bone marrow, and, 
in rare cases, the brain. There are three 
common forms. 
Type 1 is the most common. Clinical 
features include easy bruising, anemia, 
low blood platelets, enlargement of 
the liver and spleen, bone disease, and, 
in some instances, lung impairment. 
There are no signs of brain involvement. 
Problems may begin early in life, be 
delayed until adulthood, or not occur 
at all. 
In type 2, liver and spleen enlargement 
are apparent by three months of age, and 
there is extensive and progressive brain 
damage. These patients usually die by 
two years of age. 
In type 3, liver and spleen enlargement 
is variable, and signs of brain 
involvement, such as seizures, become 
apparent gradually. 
DOI: 10.1371/journal.pmed.0010021.g002
Figure 2. A Meta-Analysis of the Decrease in Liver Size in Patients with Gaucher Disease 
Documented for Various Doses of Enzyme Given As Replacement Therapy
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of recombinant human 
glucocerebrosidase (imiglucerase, 
brand name Cerezyme), suggest that 
children be given an initial dose of 
30 to 60 units every two weeks [10]. 
But there is no high-quality evidence 
that such a costly treatment regimen 
provides results superior to those 
achieved with smaller doses. The only 
support for recommending this high 
dosage comes from uncontrolled 
studies showing that in some children 
bone lesions may progress at low 
dosages. However, we know from 
our own published observations that 
skeletal progression and even fractures 
also occur in some individuals receiving 
high-dose therapy [11]. Thus, I would 
caution against any recommendations 
to give high-dose therapy that have 
not been based on well-designed 
randomized, controlled trials. Having 
said this, I recognize that most, but 
not all, of the patients that were 
included in our meta-analyses were 
adults, whereas the company-sponsored 
consensus recommendations refer 
to children. However, in the absence 
of any evidence-based rationale for 
administering large, costly doses 
of enzyme, I believe that the use of 
smaller, more frequent doses is the 
most prudent treatment approach.
It is often assumed that patients with 
severe disease require larger doses of 
enzyme than those with mild disease, 
but a meta-analysis based on liver size 
or spleen size made it clear that this 
is not the case (Figure 3) [12]. Large 
organs shrink more rapidly than 
smaller ones, and this is true regardless 
of the dose that is used [13].
Skeletal response. The 
response of enlarged 
viscera to enzyme 
infusion is much more 
rapid than the response 
of bones. In one early 
study, the large dose used 
in the pivotal trial was 
given for up to four years 
to patients with bone 
disease, and although 
the response was slow, 
gradual improvement 
occurred [14]. Strangely, 
the authors concluded 
that large doses were 
required—“strangely,” 
because they did not 
give smaller doses to any 
patient. Subsequently, 
it was shown that less than a quarter 
of the dose (only 30 units/kg/mo) 
produced an equivalent response [15].
Whom to Treat
The severity of Gaucher disease is very 
variable. We have estimated that some 
60% of patients homozygous for the 
common c.1226 C  G (N370S) mutation 
never come to medical attention 
[16]. Accordingly, many—possibly 
most—patients with Gaucher disease 
require no treatment. In adults, the 
disease is rarely progressive [11,17]. 
What you see is what you have, more 
or less. Bone fractures, of course, 
are not gradual events but sudden 
ones. But almost invariably they occur 
in patients who already have very 
substantial, demonstrable bone disease. 
In children, the situation is different, 
and progression is common. It is only 
with proper awareness of the natural 
history of the disease that one can 
make rational judgments regarding 
who needs treatment.
Individualized Treatment
Evaluating dose–response relationships 
in patients with Gaucher disease has 
been difﬁ  cult for several reasons. The 
number of new patients requiring 
therapy is relatively small, and the 
Genzyme Corporation has done little 
to encourage the performance of dose–
response studies, making it difﬁ  cult 
to enroll patients. But beyond that, 
the response of patients to any dose is 
variable. Some authors have suggested 
that this may be due to individual 
differences in dose requirements—that 
some patients are relatively resistant 
and require a large dose, while others 
do well on a small dose [18]. This is 
an attractive concept, but is it correct? 
Another meta-analysis indicates that it 
is not. Rather, there are patients who 
respond poorly to any dose and others 
who respond well to any dose [19]. 
Moreover, quadrupling the dose does 
not increase the rate of response [11].
What Does the Future Hold?
The quality of life for patients with 
Gaucher disease has been greatly 
improved by the development 
of enzyme replacement therapy. 
Manufacturing and selling the enzyme 
has also been enormously proﬁ  table for 
industry. This proﬁ  tability has served 
as a stimulus for the development of 
enzyme replacement treatments for 
diseases less common and generally 
less responsive to treatment than 
Gaucher disease. Given the small 
target population, these treatments 
are enormously costly on a per-patient 
basis. Treatments for Fabry disease 
and Hurler-Scheie disease (also called 
mucopolysaccharidosis I) are already 
licensed, and others are on the way 
[20,21,22]. This brings us face-to-face 
with a major ethical dilemma. We do 
not put a price on human life. Yet 
health-care resources are a zero-sum 
game. What is spent on one disease 
cannot be spent on another. Is it 
better to treat one child with Hurler-
Scheie disease [22] or to provide good 
prenatal care to 100 women who might 
not otherwise obtain it, or for that 
matter, to feed 1,000 malnourished 
children? These are difﬁ  cult decisions 
that will be forced on us as enzyme 
replacement and other high-technology 
therapies come of age.  
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